Patents by Inventor George J. Cianciolo

George J. Cianciolo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of including apoptosis/Cell death in leukemia cell using a purine nucleoside analogue
    Publication number: 20110319360
    Abstract: A method of inducing apoptosis or cell death in a leukemia cell includes subjecting the cell to a purine nucleotide analogue, LMP-420 (2-amino-6-chloro-9-[5(dihydroxyboryl)-pentyl] purine).
    Type: Application
    Filed: June 23, 2010
    Publication date: December 29, 2011
    Applicant: U.S. Department of Veterans Affairs
    Inventors: J. Brice Weinberg, Daphne R. Friedman, George J. Cianciolo, David A. Rizzieri
  • 9-[(5-dihydroxyboryl)-pentyl] purines, useful as an inhibitor of inflammatory cytokines
    Publication number: 20030022864
    Abstract: A compound of Formula I 1
    Type: Application
    Filed: April 24, 2001
    Publication date: January 30, 2003
    Inventors: Khalid S. Ishaq, George J. Cianciolo
  • Hydroxyalkylammonium-pyrimidines and nucleoside derivatives, useful as inhibitors of inflammatory cytokines
    Patent number: 5679684
    Abstract: Novel hydroxyalkylammonium-pyrimidine of the formula ##STR1## and nucleoside derivatives have been found to be useful as inhibitors of inflammatory cytokines. They can be used, inter alia, in the therapy of septic shock, cachexia, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and AIDS. The compounds are typically prepared by reaction of an iodo substituted nucleoside with the appropriately substituted hydroxyalkylamine.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 21, 1997
    Assignees: Macronex, Inc., The University of N.C. at Chapel Hill
    Inventors: Bradley J. Benson, Xiannong Chen, George J. Cianciolo, Jose-Luis Diaz, Khalid S. Ishaq, Susan L. Morris-Natschke, Ronald J. Uhing, Henry Wong
  • N-substituted-(Dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines
    Patent number: 5643893
    Abstract: Novel N-substituted-(dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives have been found to be useful as inhibitors of inflammatory cytokines. They can be used, inter alia, in the therapy of septic shock, cachexia, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and AIDS. The compounds are typically prepared by reaction of an bromoalkyl boronic acid with the purine, indole or pyrimidine base.
    Type: Grant
    Filed: June 22, 1994
    Date of Patent: July 1, 1997
    Assignees: Macronex, Inc., University of North Carolina
    Inventors: Bradley J. Benson, Xiannong Chen, George J. Cianciolo, Jose-Luis Diaz, Khalid S. Ishaq, Susan L. Morris-Natschke, Ronald J. Uhing, Henry Wong
  • Hydroxyalkylammonium-pyrimidines or purines and nucleoside derivatives, useful as inhibitors of inflammatory cytokines
    Patent number: 5550132
    Abstract: Novel hydroxyalkylammonium-pyrimidine of the formula ##STR1## and nucleoside derivatives have been found to be useful as inhibitors of inflammatory cytokines. They can be used, inter alia, in the therapy of septic shock, cachexia, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and AIDS. The compounds are typically prepared by reaction of an iodo substituted nucleoside with the appropriately substituted hydroxyalkylamine.
    Type: Grant
    Filed: June 22, 1994
    Date of Patent: August 27, 1996
    Assignees: University of North Carolina, Macronex, Inc.
    Inventors: Bradley J. Benson, Xiannong Chen, George J. Cianciolo, Jose-Luis Diaz, Khalid S. Ishaq, Susan L. Morris-Natschke, Ronald J. Uhing, Henry Wong
  • Process for making biologically active polypeptides based on transforming growth factor-.beta.sequences
    Patent number: 5268455
    Abstract: A polypeptide is provided that excludes (a) a full-length mature TGF-.beta. molecule or precursor TGF-.beta. molecule or deletion variants of mature or precursor TGF-.beta. molecules in which from about 1 to 10 amino acid residues have been deleted, (b) a polypeptide of the sequence: Cys-Val-Arg-Gln-Leu-Tyr-Ile-Asp-Phe-Arg-Lys-Asp-Leu-Gly-Trp-Lys, and (c) a polypeptide of the sequence: Arg-Asn-Leu-Glu-Glu-Asn-Cys-Cys-Val-Arg-Pro-Leu-Tyr-Ile-Asp-Phe-Arg-Gln-As p-Leu, the polypeptide comprising an amino acid sequence that is based on conserved sequences in the family of TGF-.beta. molecules. Such polypeptides are particularly useful therapeutically as immunosuppressive agents when coupled to carrier proteins or crosslinked to form polymers.
    Type: Grant
    Filed: January 23, 1992
    Date of Patent: December 7, 1993
    Assignee: Genentech, Inc.
    Inventor: George J. Cianciolo
  • Biologically active polypeptides based on transforming growth factor-.beta.
    Patent number: 5118791
    Abstract: A polypeptide is provided that excludes (a) a full-length mature TGF-.beta. molecule or precursor TGF-.beta. molecule or deletion variants of mature or precursor TGF-.beta.molecules in which from about 1 to 10 amino acid residues have been delected, (b) a polypeptide of the sequence: Cys-Val-Arg-Gln-Leu-Tyr-Ile-Asp-Phe-Arg-Lys-Asp-Leu-Gly-Trp-Lys, and (c) a polypeptide of the sequence: Arg-Asn -Leu-Glu-Glu-Asn-Cys-Cys-Val-Arg-Pro-Leu-Tyr-Ile-Asp-Phe-Arg-Gln-Asp-Leu, said polypeptide comprising an amino acid sequence that is based on conserved sequences in the family of TGF-.beta. molecules. Such polypeptides are particularly useful therapeutically as immunosuppressive agents when coupled to carrier proteins or crosslinked to form polymers.
    Type: Grant
    Filed: June 13, 1991
    Date of Patent: June 2, 1992
    Assignee: Genentech, Inc.
    Inventors: John P. Burnier, George J. Cianciolo
  • Biologically active polypeptides based on transforming growth factor-.beta.
    Patent number: 5061786
    Abstract: A polypeptide is provided that excludes (a) a full-length mature TGF-.beta. molecule or precursor TGF-.beta. molecule or deletion variants of mature or precursor TGF-.beta. molecules in which from about 1 to 10 amino acid residues have been deleted, (b) a polypeptide of the sequence: Cys-Val-Arg-Gln-Leu-Tyr-Ile-Asp-Phe-Arg-Lys-Asp-Leu-Gly-Trp-Lys, and (c) a polypeptide of the sequence: Arg Asn-Leu-Glu-Glu-Asn-Cys-Cys-Val-Arg-Pro-Leu-Tyr-Ile-Asp-Phe-Arg-Gln-Asp-Le u, said polypeptide comprising an amino acid sequence that is based on conserved sequences in the family of TGF-.beta. molecules. Such polypeptides are particularly useful therapeutically as immunosuppressive agents when coupled to carrier proteins or crosslinked to form polymers.
    Type: Grant
    Filed: May 25, 1989
    Date of Patent: October 29, 1991
    Assignee: Genentech, Inc.
    Inventors: John P. Burnier, George J. Cianciolo
  • Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences
    Patent number: 4822606
    Abstract: Novel peptides having immunosuppressive or immunoregulatory activity are disclosed.
    Type: Grant
    Filed: April 7, 1986
    Date of Patent: April 18, 1989
    Assignee: Duke University
    Inventors: Ralph D. Snyderman, George J. Cianciolo